CUV today announced the start of the CUV801 P2a trial - to treat AIS (arterial ischaemic stroke). You are probably aware stroke is one of the biggest killers out there.
It's a P2, and therefore a little way away from the possibility of being widely prescribed, but the commercial potential is arguably vast. This is but one of several large to possibly very large indications that the company is slowly progressing with.
It's the potential of these kind of possibilities, not the commercial potential of EPP alone, which has led to CUV forming a base of long held (but maybe tired) holders. If these trials come off, I think there's a good chance the wait will have been worthwhile.
IMO and DYOR.
Clinuvel compared to Imugene, page-10
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |